文献詳細
特集 去勢抵抗性前立腺癌(CRPC)─Key Questionsに答える
文献概要
Key Question
▶ カバジタキセルを投与するタイミングと注意すべき点は何ですか?
Direct Answer
・カバジタキセルはドセタキセル加療後のドセタキセル耐性去勢抵抗性前立腺癌に対する二次化学療法として位置づけられます.
・血液毒性として,好中球減少症に対する注意が必要です.
・発熱性好中球減少症の予防のため,G-CSF製剤の一次予防投与が推奨されます.
▶ カバジタキセルを投与するタイミングと注意すべき点は何ですか?
Direct Answer
・カバジタキセルはドセタキセル加療後のドセタキセル耐性去勢抵抗性前立腺癌に対する二次化学療法として位置づけられます.
・血液毒性として,好中球減少症に対する注意が必要です.
・発熱性好中球減少症の予防のため,G-CSF製剤の一次予防投与が推奨されます.
参考文献
1) Villanueva C, Bazan F, Kim S, et al : Cabazitaxel : a novel microtubule inhibitor. Drugs 71 : 1251─1258, 2011
2) de Bono JS, Oudard S, Ozguroglu M, et al : Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment : a randomised open-label trial. Lancet 376 : 1147─1154, 2010
3) Mukai H, Takahashi S, Nozawa M, et al : Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 73 : 703─710, 2014
4) Nozawa M, Mukai H, Takahashi S, et al : Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. Int J Clin Oncol 20 : 1026─1034, 2015
5) Omlin A, Sartor O, Rothermundt C, et al : Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel. Clin Genitourin Cancer 13 : e205─208, 2015
6) 日本泌尿器科学会 (編) : 前立腺癌診療ガイドライン2016年版. メディカルレビュー社, 東京, 2016
7) Pezaro CJ, Omlin AG, Altavilla A, et al : Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol 66 : 459─465, 2014
8) Al Nakouzi N, Le Moulec S, Albiges L, et al : Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. Eur Urol 68 : 228─235, 2015
9) Mita AC, Denis LJ, Rowinsky EK, et al : Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 15 : 723─730, 2009
10) Pivot X, Koralewski P, Hidalgo JL, et al : A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 19 : 1547─1552, 2008
11) van Soest RJ, de Morrée ES, Kweldam CF, et al : Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 67 : 981─985, 2015
12) van Soest RJ, van Royen ME, de Morrée ES, et al : Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 49 : 3821─3830, 2013
13) Angelergues A, Maillet D, Fléchon A, et al : Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. Eur J Cancer 50 : 1602─1609, 2014
14) Di Lorenzo G, D'Aniello C, Buonerba C, et al : Peg-filgrastim and cabazitaxel in prostate cancer patients. Anticancer Drugs 24 : 84─89, 2013
15) Droz JP, Aapro M, Balducci L, et al : Management of prostate cancer in older patients : updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 15 : e404─414, 2014
16) Droz JP, Balducci L, Bolla M, et al : Management of prostate cancer in older men : recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 106 : 462─469, 2010
掲載誌情報